Patent SG-11201906229Q-A (SG)
Title: Anti-ccr7 antibody drug conjugates
Inventor: BENDER STEVEN
IPC: A61K39/395
Filed: 2018-02-01
Abstract: MeanTumor Vo lume { mm 15 2:3 2.5 30 4Dose2 WV psi* 11 054 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 09 August 2018 (09.08.2018) WIP0 I PCT omit °nolo milli offi mm11E11111° oimIE (10) International Publication Number WO 2018/142322 Al (51) International Patent Classification: CO7K 16/28 (2006.01) A61K 39/395 (2006.01) A61K 47/68 (2017.01) (21) International Application Number: PCT/IB2018/050639 (22) International Filing Date: 01 February 2018 (01.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/454,476 03 February 2017 (03.02.2017) US (71) Applicant: NOVARTIS AG [CH/CH]; Lichtstrasse 35, 4056 Basel (CH). (72) Inventors: BENDER, Steven; c/o Novartis Institute for Functional Genomics, Inc., dba Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). CHARLTON, Tracy; c/o Novartis Institute for Functional Genomics, Inc., dba Genomics Institute of the Novartis Research Founda- tion, 10675 John Jay Hopkins Drive, San Diego, Califor- nia 92121 (US). GALKIN, Anna; c/o Novartis Institute for Functional Genomics, Inc., dba Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hop- kins Drive, San Diego, California 92121 (US). GEIERS- TANGER, Bernhard Hubert; c/o Novartis Institute for Functional Genomics, Inc., dba Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). GLASER, Scott Martin; c/o Novartis Institute for Functional Genomics, Inc., dba Genomics Institute of the Novartis Research Foun- dation, 10675 John Jay Hopkins Drive, San Diego, Califor- nia 92121 (US). KASIBHATLA, Shailaja; 13073 Dres- sage Lane, San Diego, California 92130 (US). KNUTH, Mark; c/o Novartis Institute for Functional Genomics, Inc., dba Genomics Institute of the Novartis Research Founda- tion, 10675 John Jay Hopkins Drive, San Diego, Califor- nia 92121 (US). ROTTMANN, Sabine; c/o Novartis In- stitute for Functional Genomics, Inc., dba Genomics Insti- tute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). RUE, (54) Title: ANTI-CCR7 ANTIBODY DRUG CONJUGATES Days post-implant •••• No treatment hIgG1-CysMab.DAPA MPET-DM4 5mg/kg ▪ 121612.CysMab.DAPA.MPET.DM4 0.5 mg/kg -10- 121G12.CysMab.DAPA.MPET.DM4 2 mg/kg ▪ 121612.CysMab.DAPA.MPET.DM4 5 mg/kg \"ztv . 121G12.DAPA.sSPDB.DM4 0.5 mg/kg 121612.DAPA.sSPDB.DM4 2 mg/kg 121612.DAPA.sSPDB.DM4 5 mg/kg Figure 10 I I - (57) : This application discloses anti-CCR7 antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding © fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents. O [Continued on next page] WO 2018/142322 Al MIDEDIMOMOIDEIREEMOMMIEMIMOHOIRVOIMIE Sarah; c/o Novartis Institute for Functional Genomics, Inc., dba Genomics Institute of the Novartis Research Founda- tion, 10675 John Jay Hopkins Drive, San Diego, Califor- nia 92121 (US). SPRAGGON, Glen; c/o Novartis Insti- tute for Functional Genomics, Inc., dba Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hop- kins Drive, San Diego, California 92121 (US). UNO, Tet- suo; c/o Novartis Institute for Functional Genomics, Inc., dba Genomics Institute of the Novartis Research Founda- tion, 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). (74) Agent: NOVARTIS AG; Lichtstrasse 35, 4056 Basel (CH). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(i)) Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE